| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.39B | +260.2% |
| Gross profit | $-0.57B | — |
| Operating income | $-1.39B | — |
| Net income | $-1.34B | — |
| Gross margin | -145.5% | Net margin -345.2% |
| Segment | Revenue | Share |
|---|---|---|
| COVID19 | $0.34B | 88.7% |
| Stand Ready Manufacturing | $0.03B | 8.2% |
| RSV | $0.01B | 1.8% |
| Collaboration Arrangement Including Arrangements With Affiliate | $0.01B | 1.3% |
| Grant | $0.00B | 0.0% |
| License And Royalty | $0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.95B | 245.5% |
| R&D | $0.65B | 166.8% |
| Tax & other | $-0.04B | -11.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
TAP ・ MDLZ ・ MPWR ・ MNST ・ MCO ・ MS ・ MOS ・ MSI ・ MSCI ・ NDAQ ・ NTAP ・ NFLX
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies